KRAS and colorectal carcinoma: The RAS gene family is especially well studied due to reports that 30–50% of colorectal tumors contain mutant KRAS oncogenes, while mutations in oncogenic RAS isoforms, such as NRAS and HRAS, are responsible for an estimated additional 6% of CRC tumors (Valtorta et al., 2013; Chang et al., 2016).